TCA-101 is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TCA-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TCA-101 overview

TCA-101 is under development for the treatment of endometrial and ovarian cancer. It is administered through parenteral route. The therapeutic candidate comprises of retroviral vector-transduced autologous T cells to express anti-ALPP chimeric antigen receptors (CARs).

TCR Cure Biopharma Technology overview

TCR Cure Biopharma Technology (Tiankeya), a cutting-edge company in the field of immune cell therapy. The company is headquartered in China.

For a complete picture of TCA-101’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.